Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17472165 | 1.00 | CYP2D6 (0.33) | CYP2D6SMN1; SMN2LMNAMAPK1HIF1A | |
| SCHEMBL17472212 | 0.84 | CYP2D6 (0.34) | CYP2D6SMN1; SMN2LMNAMAPK1HIF1A | |
| SCHEMBL17274126 | 0.78 | OGA (0.31) | — | |
| SCHEMBL16154907 | 0.76 | KDM4E (0.33) | — | |
| SCHEMBL17472194 | 0.75 | OGA (0.30) | — | |
| SCHEMBL17273886 | 0.75 | OGA (0.30) | — | |
| SCHEMBL16155046 | 0.74 | IDO1 (0.36) | — | |
| SCHEMBL16155033 | 0.74 | IDO1 (0.36) | — | |
| SCHEMBL17472164 | 0.72 | — | — | |
| SCHEMBL18676120 | 0.72 | SLC5A2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015175875-A1 | AMPHOTERICIN B DERIVATIVE WITH REDUCED TOXICITY | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-11-19 | — | — | WO | disclosed |